Two years ago, a pharma sponsor asked the FDA a simple question: “Can we use AI to identify patients most likely to respond to our therapy?” The answer, in essence, was “it depends, and we’ll figure it out together.” That answer no longer holds. In the span of twelve months, the FDA and EMA have moved from case-by-case improvisation to the most significant AI...